Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis

Item

http://www.wikidata.org/entity/Q37453020

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Randomized Crossover Compariso ...... ents with Rheumatoid Arthritis

@en

Randomized Crossover Compariso ...... nts with Rheumatoid Arthritis.

@nl

type

Item

label

Randomized Crossover Compariso ...... ents with Rheumatoid Arthritis

@en

Randomized Crossover Compariso ...... nts with Rheumatoid Arthritis.

@nl

prefLabel

Randomized Crossover Compariso ...... ents with Rheumatoid Arthritis

@en

Randomized Crossover Compariso ...... nts with Rheumatoid Arthritis.

@nl

P1476

Randomized Crossover Compariso ...... ents with Rheumatoid Arthritis

@en

P2093

Alfred Cividino

http://www.w3.org/2001/XMLSchema#string

Andrew N Payne

http://www.w3.org/2001/XMLSchema#string

Johan Vanhoof

http://www.w3.org/2001/XMLSchema#string

Kristina Unnebrink

http://www.w3.org/2001/XMLSchema#string

Peter Nash

http://www.w3.org/2001/XMLSchema#string

Rita Tarzynski-Potempa

http://www.w3.org/2001/XMLSchema#string

Stephen Hall

http://www.w3.org/2001/XMLSchema#string

Udayasankar Arulmani

http://www.w3.org/2001/XMLSchema#string

P2860

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab).

A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.

Clinical significance of reported changes in pain severity.

P2888

s40744-016-0041-3

P304

257-270

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40744-016-0041-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kristina Unnebrink

P577

2016-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27747583

http://www.w3.org/2001/XMLSchema#string

P921

adalimumab

P932

5127965

http://www.w3.org/2001/XMLSchema#string